Clinical hepatocyte transplantation is hampered by low engraftment rates and gradual loss of function resulting in incomplete correction of the underlying disease. Preconditioning with partial hepatectomy improves engraftment in animal studies. Our aim was to study safety and efficacy of partial hepatectomy preconditioning in clinical hepatocyte transplantation. Two patients with Crigler-Najjar syndrome type I underwent liver resection followed by hepatocyte transplantation. A transient increase of hepatocyte growth factor was seen, suggesting that this procedure provides a regenerative stimulus. Serum bilirubin was decreased by 50%, and presence of bilirubin glucuronides in bile confirmed graft function in both cases; however, graft function was lost due to discontinuation of pretransplant concentrations after %600 days. In both cases, loss of graft function was temporally associated with emergence of human leukocyte antigen donorspecific antibodies (DSAs). In conclusion, partial hepatectomy in combination with hepatocyte transplantation was safe and induced a robust release of hepatocyte growth factor, but its efficacy on hepatocyte engraftment needs to be evaluated with additional studies. To our knowledge, this study provides the first description of de novo DSAs after hepatocyte transplantation associated with graft loss.
Introduction
Crigler-Najjar syndrome type I (CN-I) is a rare autosomal recessive metabolic liver disease caused by complete deficiency of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). Patients are at risk of developing severe and irreversible brain injury due to neurotoxicity of unconjugated hyperbilirubinemia. Therapy consists of daily phototherapy for 8-14 h, converting hydrophobic unconjugated bilirubin into water-soluble isomers (1); however, phototherapy becomes less effective with increasing age and constitutes a substantial impairment of quality of life. Finally, most patients undergo liver transplantation, reducing the risk of brain injury.
Hepatocyte transplantation is a novel treatment for CN-I because replacement of a fraction of UGT1A1 decreases serum bilirubin. To date, 10 patients with CN-I have received hepatocyte transplantations (2) . In most patients, serum bilirubin decreased. Nevertheless, all patients eventually underwent liver transplantation because of graft loss or insufficient improvement of quality of life.
Insufficient engraftment and long-term function of donor hepatocytes are the major limitations in clinical hepatocyte transplantation. Although hepatocytes have an enormous capacity to proliferate, they do not express this capacity unless a mitotic stimulus is present. Liver resection is the strongest proliferation stimulus, and it improves hepatocyte engraftment in animal studies (3) .
The aim of this study was to evaluate safety and outcome of partial hepatectomy preconditioning in clinical hepatocyte transplantation. In addition, growth factors and cytokines controlling liver regeneration were studied. Finally, recipients were evaluated for human leukocyte antigen (HLA) antibodies, which are associated with graft failure in islet, kidney and heart transplantation (4, 5) . In hepatocyte transplantation, testing for HLA antibodies is rarely reported, and their role has not been established.
Methods
Patients CN-I was confirmed by lack of bilirubin conjugates in bile and UGT1A1 mutation analysis. Patient 1, a 13-year-old boy, was found to be homozygous for 1124C > T mutation resulting in an amino acid change at codon 375 (S375F). Patient 2, an 11-year-old girl, was found to be a compound heterozygote for 1-2_14 deletions (del) of 16 base pairs (bp) resulting in a premature stop codon and 608_631 del 24 bp resulting in the loss of eight amino acids. Both received 7-9 h of phototherapy and were unresponsive to phenobarbital. No signs of encephalopathy were noted, and electroencephalography was normal. Patient 1 was 158 cm tall (45th percentile) and weighed 69 kg (>95th percentile) with a BMI of 27.6 (>95th percentile), and patient 2 was 151 cm tall (70th percentile) and weighed 40 kg (50th percentile) with a BMI of 17.3 (40th percentile). Serologic tests for hepatitis B and C and human immunodeficiency virus were negative for both patients. Liver chemistry was normal except that both patients showed slightly elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum (ALT: 0.6-2 microkatals (mkat) per liter [reference <1.2 mkat/l]; AST: 0.7-1.1 mkat/l [reference <0.7 mkat/l]). Hepatic ultrasound in patient 1 showed irregular echogenicity. Pretransplant liver biopsy showed fibrosis stage 2 (Batts and Ludwig classification) and no signs of inflammation or steatosis. In patient 2, abdominal ultrasound and pretransplant liver histology were normal.
Approval by the regional ethics committee (2010/840-31) and informed consent from the patients and parents were obtained.
Hepatocyte isolation
Hepatocytes were isolated from deceased donor livers by collagenase perfusion using CIzyme (VitaCyte LLC, Indianapolis, IN) ( Table 1) . Cell number, hepatocyte yield, cytochrome P450, caspase activity and adenosine triphosphate (ATP) content were analyzed, as described previously (6) . Immunocytochemistry of cell smears was performed on a Leica Bond-III immunostainer using the following antibodies: CD45, CD31 and CK18 (Novocastra) and CD68 (Dako).
Partial hepatectomy and hepatocyte transplantation
A catheter was advanced to the main portal vein under fluoroscopy guidance accessing the umbilical vein or the mesenteric vein. Liver resection of segment 2/3 was performed before the first transplantation by cavitron ultrasonic surgical aspirator.
Hepatocytes were infused by a pump with continuous monitoring of portal pressure. Doppler ultrasound of the liver was performed regularly. Immunosuppression consisted of induction with basiliximab and 500 mg methylprednisolone followed by taper to 5 mg prednisolone daily. Tacrolimus was given with trough concentrations of 10-13 ng/ml for the first month and 6-8 ng/ml thereafter. Patient 1 received mycophenolate mofetil 1 g twice daily during the first 6 days.
Immunological investigation
Complement-dependent cytotoxicity (CDC) and flow cytometry crossmatch (fluorescence-activated cell sorting [FACS] ) were performed, as described previously (7). Luminex-based LABScreen-PRA and Single Antigen assay (One Lambda) were used to test for anti-HLA antibodies before and every 3-4 mo after transplant. Complement binding was evaluated by C1q assay with single-antigen beads. Reactivity was normalized for background and expressed as mean fluorescence intensity (MFI). MFI values >1000 were considered positive.
Autoantibodies and UGT1A1 antibodies
Antinuclear antibodies (ANA) were analyzed by indirect immunofluorescence (Immuno Concepts) and multiplex ANA assay (BioPlex 2200; Bio-Rad). Antimitochondrial and liver-specific autoantibodies were analyzed by line immunoassay (Euroimmun). Anti-smooth muscle antibodies were evaluated by indirect immunofluorescence assay (Kallestad). Antibodies against UGT1A1 were evaluated by enzyme-linked immunosorbent assay (ELISA) (8) .
Bilirubin conjugates
Bilirubin conjugates in bile were analyzed, as described previously (8).
Growth factors and cytokines
Human hepatocyte growth factor (HGF) was quantified by ELISA (R&D Systems). Serum epidermal growth factor (EGF), tumor necrosis factor a (TNF-a) and IL-6 were analyzed by the Luminex human cytokine kit (Merck).
Liver tissue engraftment
Male donor cells were detected by polymerase chain reaction for the sexdetermining region Y (SRY) gene (Quantifiler DNA Kit; Applied Biosystems).
Results

Hepatocyte viability and function
Cold ischemia time ranged from 5 to 35 h. Viability was 87-100%, and hepatocyte yield was 9-65 Â 10 6 per gram. ATP content, cytochrome P450 and caspase 3/7 activities were adequate compared with historical controls (Table 1) . The majority of cells were CK18 positive with low-level contamination by nonparenchymal cells ( Figure S1 ).
Intraportal infusion
Portal pressure was unchanged after liver resection but increased after each hepatocyte infusion ( Figure 1 ) and normalized within 24 h after infusion. Repeated Doppler ultrasound showed normal portal vein flow without thrombosis. Heart rate, oxygen saturation, central venous pressure and pulmonary artery pressure did not change during the procedure.
Clinical course Patient 1 received two transplantations from different donors 3 mo apart, with 2.2 and 9 Â 10 9 hepatocytes, respectively (Table 1) . Total bilirubin ranged before transplant from 416 to 450 mmol/l and increased after surgery to peak on day 7 at 490 mmol/l, followed by a decline to 320-350 mmol/l (Figure 2) . A decrease to 220-240 mmol/l was observed after the second transplant. After each transplantation, serum conjugated bilirubin and ALT transiently increased. On day 212, a sudden increase of total bilirubin associated with diagnosis of crusted scabies was noted. Despite lowering of the tacrolimus dose and anthelmintic treatment, scabies recurred. The interpretation was that the hepatocyte graft was lost. Because of recurring scabies and risk of encephalopathy, immunosuppression was discontinued, and the patient listed for liver transplantation. Twelve days after discontinuation of immunosuppression, the patient was readmitted for intensified phototherapy due to increased serum bilirubin. During this stay, the patient developed fever, abdominal pain and elevated C-reactive protein, ALT, pancreatic amylase (5.8 mkat/l) and leukocytes (18.1 Â 10 9 /l) ( Figure 2 ). Total bilirubin decreased to 300 mmol/l, and conjugated bilirubin temporarily increased to 51 mmol/l. Hepatic ultrasound was normal, without signs of thrombosis, cholestasis or gallstones. The patient was treated with intravenous antibiotics and recovered without sequelae within 7 days. On day 580, the patient underwent liver transplantation with an ABO-identical organ from a deceased donor. Serum bilirubin normalized within 2 days, and postoperative course was uncomplicated. A mild rejection at 4 months was reversed by increasing the tacrolimus dose. At 1 year after transplantation, the patient was in good condition with excellent graft function.
Patient 2 received 5.3 Â 10 9 viable hepatocytes in six infusions in a single transplantation event over 17 h. Serum bilirubin before transplantation ranged from 400 to 450 mmol/l and increased after transplantation to 540 mmol/l on postoperative day 17, followed by a continuous decline to 190 mmol/l, and remained at 50% of pretransplant concentrations for >6 mo (Figure 3) . ALT increased temporally after transplantation to 7.4 mkat/l and remained elevated between 1.3 and 2.8 mkat/l thereafter. After 6 mo, serum bilirubin increased progressively over a period of 500 days to pretransplant values. Due to increasing risk of brain injury, patient 2 was listed for liver transplantation. On day 951, the patient received an ABOidentical organ from a deceased donor. Serum bilirubin normalized within 2 days, and the postoperative course was uncomplicated. At 6 weeks after transplantation, the patient's condition and graft function were excellent.
Safety
No procedure-related complications were noted. Liver resection was performed without transfusion of blood products. Two major complications were noted in patient 1. One was mycophenolate intoxication on day 7, with blood concentration of 8.7 times the upper limit associated with diarrhea and abdominal pain. The other complication was the scabies infection. No major adverse events were noted in patient 2.
Bilirubin conjugates
Pretransplant bile did not contain bilirubin diglucuronides and contained only small amounts of bilirubin monoglucuronide, whereas posttransplant samples showed 4% (patient 2) and 57% (patient 1) bilirubin diglucuronides (Figure 4 ). Growth factors and cytokines HGF and EGF were released in patient 1, whereas in patient 2, only HGF was released after partial hepatectomy and hepatocyte transplantation. Interestingly, HGF and EGF concentrations increased even after the second infusion in patient 1, without partial hepatectomy. In contrast, IL-6 and TNF-a decreased after transplantation, and concentrations remained low ( Figure 5 ).
Assessment of antibody formation
Donor and recipient HLA types are summarized in Table 2 . Pretransplant CDC and FACS crossmatch were negative for all three cell infusions. Both patients tested negative for HLA antibodies before transplantation. Neither patient received blood transfusions during the study period.
Patient 1 developed HLA antibodies 27 days after discontinuation of immunosuppression, corresponding to 1 week after admission due to fever. Panel reactive antibodies (PRA) increased to 100% for class I and 26% for class II, and a subset of these were donor-specific antibodies directed against both donors (Table 3; Figure 2 ). Analysis of complement binding showed C1q binding to HLA Cw7. Repeated FACS crossmatch with serum from days 456 and 580 and stored lymphocytes from donors 1 and 3, respectively, were positive for both T and B cells.
In patient 2, de novo HLA antibodies were detected 670 days after hepatocyte transplantation on maintenance immunosuppression. PRA increased to 18% for class I and 89% for class II, and a subset of these were donor specific and C1q positive (Figure 3 ; Table 4 ). Repeated FACS crossmatch with serum taken at days 674 and 740 and stored donor lymphocytes were positive for both T and B cells.
Analysis of serum from both patients at time points with high levels of HLA antibodies did not show the presence of anti-UGT1A1 antibodies or ANA, antimitochondrial, liverspecific, or anti-smooth muscle autoantibodies.
Analysis of liver tissue engraftment
Histology of explanted liver revealed no inflammation, steatosis or signs of portal microthrombi; however, fibrosis grade was increased in both patients, in patient 1 from grade 2 to 2-3 and in patient 2 from grade 1 to 2, compared with pretransplant biopsies ( Figure S2 ). In patient 2, donor cell engraftment was analyzed by SRY analysis. Male cells could be detected only at low levels in the single-protocol biopsy taken 2 mo after hepatocyte transplantation, whereas samples before hepatocyte transplantation and 52 liver biopsies covering the entire liver explant did not show amplification (data not shown).
Discussion
A major limitation of clinical hepatocyte transplantation is the limited repopulation of the liver with donor hepatocytes. In animal models, 50-90% of the liver can be replaced using surgical, genetic or chemical preconditioning (2) . A consensus meeting in 2011 suggested liver resection preconditioning to increase repopulation with donor hepatocytes (9) . At experienced hepatobiliary centers, perioperative safety and experience have increased, and liver resection has been used previously in an ex vivo gene therapy trial for familial hypercholesterolemia (10).
This study evaluated safety and feasibility of partial hepatectomy preconditioning and hepatocyte transplantation in CN-I. Both patients tolerated liver surgery well, without procedure-related complications. A concern was related to the risk of increased portal pressure after resection potentiating the risk of portal thrombosis (11) . In this study, portal pressure did not increase after liver resection but strongly increased after hepatocyte infusion; however, the increase in portal pressure observed was comparable to previous reports without liver resection (12) . Another concern was related to the risk of surgical complications in consecutive liver transplantation due to distorted anatomy (13) . In both patients, adhesions close to the resection site were found but did not result in any complications, prolonged operation time or bleeding.
The mitogenic stimulus of liver resection was evaluated. At 2 h after liver resection, serum HGF increased 20-fold and remained elevated for up to 25 days. A similar pattern could be seen for EGF; however, TNF-a and IL-6 decreased after transplantation. A possible explanation of this decline might be the immunosuppressive medication known to inhibit TNF-a and IL-6 expression (14) . Interestingly, serum HGF also increased after the second hepatocyte transplantation in patient 1. In contrast to the first transplantation, serum HGF normalized within 2 days after hepatocyte infusion. We hypothesize that the increase in HGF by hepatocyte transplantation was caused by portal microembolization with donor hepatocytes, similar to preoperative portal vein embolization in liver surgery (15) . This also coincided with the increase in portal pressure, which led us to speculate that increased portal pressure during the infusion might not be simply a side effect but actually could be beneficial for engraftment. 2474  5380  7831  6095  A36  2306  3495  5253  2301  A80  1901  2595  4095  ND  A2  1385  1955  2791  2377  A43  1383  2632  4919  ND  A66  ND  3149  5693  5296  A34  ND  3125  4977  4718  A3  ND  3086  4997  ND  A74  ND  3058  4958  3765  A31  ND  2977  4899  2849  A29  ND  2917  4501  ND  A68  ND  2869  4435  5646  A26  ND  2821  5730  ND  A33  ND  2634  4470  3360  A30  ND  2561  4057  4665  A69  ND  2352  4564  6202  A25  ND  2224 MFI values and C1q positivity for patient 2 on days 674, 740, 814, and 1062 after hepatocyte transplantation. Day 1062 is 111 days after liver transplantation. C1q reactivity was normalized to background, and MFI values >1000 were considered positive. þ, positive; MFI, mean fluorescence intensity; NA, not available; ND, below threshold limit of 1000 MFI.
To date, 10 cases of human hepatocyte transplantation for patients with CN-I have been reported (2) . Patient ages ranged from 1 to 10 years, and weight ranged from 7.4 to 38 kg. The cell dose administered in these studies was 160-680 Â 10 6 per kilogram of body weight, corresponding to a theoretical liver mass of 4-17% (2). In comparison to these studies, the patients reported in our study were older and heavier. The cell dose administered was significantly lower, with 133 and 166 Â 10 6 hepatocytes per kilogram of body weight corresponding to liver masses of 3.3% and 4.2%, respectively. Notwithstanding this low dose, both patients showed a strong decrease of serum bilirubin. The most sensitive measurement of hepatic bilirubin glucuronidation activity is the presence of bilirubin glucuronide in bile. Only one study investigated bile for bilirubin conjugates (16) . Similar to Fox et al, we detected bilirubin mono-and diglucuronides after transplantation.
Two major complications unrelated to the surgical procedure occurred in patient 1. First, he presented on day 7 with mycophenolate intoxication. Mycophenolate is primarily metabolized by glucuronidation by UGT1A9 and UGT2B7 but not UGT1A1 (17) ; however, accumulation of mycophenolate is explained by the mutation involving exon 4 of the UGT1A1 gene and thus affecting all UGT1A isoforms (18) . Second, 6 mo after transplantation, patient 1 presented with crusted scabies (Scabies norvegica) infection, a particularly severe form found in immune-compromised patients.
The best immunosuppressive protocol for clinical hepatocyte transplantation is unknown, and most centers have adopted the immunosuppressive protocol used in liver transplantation. Hepatocytes have tolerogenic properties, and initially it was believed that immunosuppressive therapy might not be necessary (19) ; however, Allen et al reported a cellular alloresponse directed against donor class I HLA associated with hepatocyte graft loss (19) . No DSAs were detected in this patient. Bumgardner et al showed that hepatocyte rejection was not associated with DSAs in mice (20) . We report the emergence of DSAs directed against both class I and II and associated with graft loss. Interestingly, in patient 1, DSAs directed against both hepatocyte donors could be detected. In this patient, antibody formation was induced by discontinuation of immunosuppression, whereas in patient 2, DSAs developed during adequate immunosuppressive therapy. Our results suggest involvement of humoral immunity in rejection of allogenic hepatocytes. A limitation of our study is that we had no histopathologic evidence of humoral rejection, and cellular immunity was not investigated. Nevertheless, our results show a high level of DSAs long term after hepatocyte transplantation associated with graft loss, emphasizing the need for studies of HLA antibodies in hepatocyte transplantation. Preformed and de novo DSAs are well-known risk factors for decreased graft survival after kidney, heart and islet transplantation (4, 5) . Until recently, DSAs were considered irrelevant in liver transplantation; however, current data suggest that DSAs may cause allograft injury and affect overall outcome (4) . Emergence of DSAs after hepatocyte transplantation is concerning. Just as in islet transplantation, multiple donor infusions are often required, potentiating the risk of broad sensitization. This may have a negative impact if subsequent hepatocyte, liver or kidney transplantation should be necessary.
To our knowledge, this study is the first report of de novo DSAs after clinical hepatocyte transplantation. Graft function loss was temporally associated with antibody formation. Partial hepatectomy alone or with hepatocyte infusion induced a robust release of HGF into the circulation, and a relatively low cell dose provided significant hepatocyte function. The influence of cell number, infusion flow rates and portal pressure on HGF release and the efficacy of partial hepatectomy preconditioning are worthy of additional investigation.
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